|
|
Post by selluwud on Sept 23, 2022 14:10:09 GMT
I'll take whatever I can get, just when things look the darkest.
Athersys Amends Securities Purchase Agreement In Connection With Recent Registered Direct Offering; Provides Additional Financial Flexibility In Exchange For New Warrants With A $6.385 Exercise Price
|
|
athx1
New Member
Posts: 7
|
Post by athx1 on Sept 28, 2022 19:25:52 GMT
Interesting that Schwab is back to borrowing shares
|
|
|
|
Post by omstem on Oct 7, 2022 3:17:52 GMT
Some how this message board on ATHX had been very silent. There were lot of good inputs though we all observe things and come to our our own conclusions which may or may not pan out. But there is good logic, reasoning and experience behind the posts that I always respected. Even Warren Buffet's all investments may not have paid out. What do the team here interpret from today's update? We may be right or wrong. But is the general observation? I feel that Dan feels confident. But at what cost is the question. Like JCK said previously, if the current share holders are diluted forever this is not good for the current bag holders. For Dan the PPS has to be above $22 for his Options to be fruitful. But he being the CEO can be awarded more at lower levels even if he shows some little degree of improvement. But he has his personal investment that he pumped in which is not a small amount for retail investor like me. Let us see how that pans out. Good luck all.
|
|
|
|
Post by imz72 on Oct 7, 2022 14:11:22 GMT
Dan didn't really invest his own money in the company. He received a signing grant of $300k of which he used $100k to buy shares. Of course, he has an interest in raising the share price, but he will do well even if he doesn't succeed. Look at BJ who found a job in a $2 billion company. The future of the Athersys depends mainly on 3 factors that will should transpire (or not) soon: - The PMDA's position regarding stroke approval (and to a lesser extent ARDS) - The medical community's reaction to the Treasure results - Athersys' ability to form non-dilutive partnerships It will also be interesting to see if SanBio gains approval, which could happen before the end of the year: old.reddit.com/r/ATHX/comments/xfangb/sanbios_president_says_he_is_confident_about_the |
|
goose
Junior Member
Posts: 84
|
Post by goose on Oct 7, 2022 15:48:12 GMT
Dan didn't really invest his own money in the company. He received a signing grant of $300k of which he used $100k to buy shares. Of course, he has an interest in raising the share price, but he will do well even if he doesn't succeed. Look at BJ who found a job in a $2 billion company. The future of the Athersys depends mainly on 3 factors that will should transpire (or not) soon: - The PMDA's position regarding stroke approval (and to a lesser extent ARDS) - The medical community's reaction to the Treasure results - Athersys' ability to form non-dilutive partnerships It will also be interesting to see if SanBio gains approval, which could happen before the end of the year: old.reddit.com/r/ATHX/comments/xfangb/sanbios_president_says_he_is_confident_about_theGreat points. I would argue that the 3x stroke enrollment and Multistem presentations at Grand Rounds is strong indication of a change in the medial community’s view. |
|
|
|
Post by Hockeystickchart on Oct 7, 2022 16:11:09 GMT
Nice, Goose!
I would love to have the opportunity to hear about one of those 5 upcoming Grand Rounds, both to hear the presentation, and the reaction by neurologists that are previously naive to MultiStem. Shouldn't be too hard to figure out where these rounds are. Anyone able to go? From the webinar transcript:
Athersys is working against the clock, but yeah. When stroke specialists notice outliers - and based on what we've seen of the data, they will, even in a blinded study - things will get interesting. Now we just need imz's catalysts.
|
|
|
|
Post by tmfbmf on Oct 24, 2022 15:37:51 GMT
|
|
|
|
Post by imz72 on Oct 24, 2022 17:49:48 GMT
|
|
|
|
Post by imz72 on Oct 26, 2022 10:31:42 GMT
World Stroke Congress 2022 (Singapore, October 26, 2022)
RESULTS OF TREASURE #WSC2022 showed that primary & secondary endpoints not significant in between Multistem treatment grp & placebo. However rate of Global Stroke Recovery indicated independent life after 1 yr was possible for 27% of treatment group vs 15% in a post-hoc analysis 
|
|
|
|
Post by sammy1 on Nov 9, 2022 4:11:16 GMT
Hi Jckrdu.....based on some of the recent news, it would be great to hear your thoughts on where you see this company going. Any realistic potential for optimism in the next few months? Always appreciate hearing your thoughts. thank you
|
|
toro
New Member
Posts: 19 
|
Post by toro on Nov 9, 2022 17:49:00 GMT
I'm ready to jump in on the lawsuit. That's the recourse I see.
|
|
toro
New Member
Posts: 19
|
Post by toro on Nov 9, 2022 19:00:01 GMT
To be clear, I'm not aware of any lawsuit. It's just a reflex answer.
|
|
|
|
Post by selluwud on Nov 10, 2022 13:24:13 GMT
To be clear, I'm not aware of any lawsuit. It's just a reflex answer. Get the embalming fluid ready, the grave is being dug. |
|
|
|
Post by omstem on Dec 12, 2022 20:36:29 GMT
Amgen is buying Horizon for 28.5 Billion. This was the company Dan had left. Even during the time he had joined ATHX, the MC of Horizon was around 18 Billion and ATHX was around 180 Mil. We all thought he knew what he was doing. He perhaps can still pull a surprise. GLTA.
|
|
|
|
Post by jckrdu on Dec 12, 2022 20:52:23 GMT
Hi Jckrdu.....based on some of the recent news, it would be great to hear your thoughts on where you see this company going. Any realistic potential for optimism in the next few months? Always appreciate hearing your thoughts. thank you Hey Sammy, I've been off the boards for awhile. On ATHX, I've been averaging down as I believe there are reasonably good odds Dan gets a partnership done before they run out of cash again on or about 3/31/2023. IMO, the last brutal raise of only $5M at the $1.10 pps was done to give them enough cash runway to get the partnership done. We'll see. Stock is now trading at .03 pre-split off the .02 pre-split floor, and can certainly recover if Dan gets any kind of a decent partnership done. Per the recent Reddit thread, Dan is expressing confidence that a deal will get done in Q1 2023. Again... we'll see if a deal gets done and the terms, but I'm adding in anticipation of a decent deal with 1 caveat... The caveat is that in the last earnings call, Dan made a statement that they could only raise $5M in the last offering because they were out of headroom on the existing shelf offering. IMO, that implies that a new shelf SEC filing will be coming... before the partnership. I'm keeping some cash available in the event the pps briefly tanks on the shelf filing. GL all. |
|
|
|
Post by twenty2 on Dec 22, 2022 5:02:16 GMT
|
|
|
|
Post by omstem on Jan 10, 2023 19:02:08 GMT
Last 3 to 4 sessions have been surprisingly good ATHX which is rarest of the rare things for ATHX. Keeping fingers crossed (which are already burnt).
GLTA.
|
|
|
|
Post by twenty2 on Jan 12, 2023 6:27:02 GMT
(Jan. 11, 2023) Interview (Q&A) with Hardy Kagimoto (Healios) - On a mission is to foster a healthy society
Partial, from the interview...Q: We know that earlier in the summer of 2022 you conducted a trial called TREASURE Study for Ischemic Stroke with MultiStem®. Could you give us your take on the results of that trial?Hardy Kagimoto: It comes back to the challenge of efficacy, essentially the effectiveness of the product. In order to really understand the effectiveness of the product you have to give it to the patient. We have clearly shown the tendency of efficacy with ARDS, of which trial calle ONE-BRIDGE Study and patients can get rid of ventilator 9 days earlier, and the mortality rate went down from 42.9% to 26.3%. Now we can save patients. We were given 5 patients caused by COVID-19 and there were no mortalities, and the ventilator was withdrawn within 28 days for all patients and in 3 days or less for 3 of 5 patients. This was a clear win, so we expected that one to be approved, but unfortunately they didn’t.The bottom line is that this product works. The next question then becomes, does the sale work or not? I think it checks the yes box in that respect. Unfortunately, PDMA didn’t want to see more data on this, but when it comes to ischemic stroke the data is really interesting. We found that those that had the therapy saw the efficacy go up over time, and to be honest over such a long period we did not believe that we would see efficacy. We have seen the data from the United States though, that shows efficacy on day 90, and even on the 1-year data point, which by the way showed the effectiveness to be even stronger. Honestly speaking, we found it hard to trust the data, traditionally medicine peaks out, and after that goes down, and we felt like this is what the case was going to be here too. It is real, however, and we have seen it with our own eyes.If our parents have suffered from a stroke, then the 90-day treatment isn’t going to matter, it is more of a case of long-term management. This is what we have found through phase 2 and phase 3 human clinical trials. Our partner in USA is running the phase 3 trial and they are trying to change the endpoint from 90 days to 1 year. With cell therapy, especially with somatic stem cells, there is a learning process to really find out how the cell works with certain diseases. With ARDS we designed the study to work because we already knew how the cells would react. Ischemic strokes are a more complex disease, and even to this day we still do not know why effectiveness is stronger over one year. This is something we have to learn, but first, we have to get it approved. (END of Partial)tweet tweet tweet...
(CLICK - Read replies)
twenty2
|
|
|
|
Post by jckrdu on Jan 31, 2023 14:52:18 GMT
Hi Jckrdu.....based on some of the recent news, it would be great to hear your thoughts on where you see this company going. Any realistic potential for optimism in the next few months? Always appreciate hearing your thoughts. thank you Hey Sammy, I've been off the boards for awhile. On ATHX, I've been averaging down as I believe there are reasonably good odds Dan gets a partnership done before they run out of cash again on or about 3/31/2023.
IMO, the last brutal raise of only $5M at the $1.10 pps was done to give them enough cash runway to get the partnership done. We'll see.Stock is now trading at .03 pre-split off the .02 pre-split floor, and can certainly recover if Dan gets any kind of a decent partnership done. Per the recent Reddit thread, Dan is expressing confidence that a deal will get done in Q1 2023. Again... we'll see if a deal gets done and the terms, but I'm adding in anticipation of a decent deal with 1 caveat... The caveat is that in the last earnings call, Dan made a statement that they could only raise $5M in the last offering because they were out of headroom on the existing shelf offering. IMO, that implies that a new shelf SEC filing will be coming... before the partnership. I'm keeping some cash available in the event the pps briefly tanks on the shelf filing. GL all. Still bullish here (with noted risks) per the red text above in my last post. I like the risk/reward given the very low float of Athersys at the moment. Because of the reverse, there's only 17.9M shares outstanding which is VERY small.Any partnership news announced over the next 1-2 months would likely cause a serious spike. Get it done Dan. GL all. |
|
|
|
Post by twenty2 on Mar 14, 2023 20:21:31 GMT
Anyone else not able to access ALL of Reddit and ATHX Reddit??? I received this ERROR MESSAGE...Reddit
Identified - We've identified an internal systems issue and are working to determine a fix.
Mar 14, 2023 - 12:56 PDT
Investigating - Reddit is currently offline. We're working to identify the issue.
Mar 14, 2023 - 12:18 PDT
www.reddit.com/r/ATHX/
twenty2
PS. (5:30 pm PT) Back On!...
|
|
